Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
about
Cardiac fibrosis in myocardial infarction-from repair and remodeling to regenerationAngiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes.Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy.
P2860
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
@ast
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
@en
type
label
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
@ast
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
@en
prefLabel
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
@ast
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
@en
P2093
P2860
P921
P1476
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
@en
P2093
C Corinaldesi
C Crescioli
L Di Luigi
P2860
P2888
P304
P356
10.1007/S40618-015-0340-5
P577
2015-06-28T00:00:00Z
2016-02-01T00:00:00Z